Trading Update
Sigma Healthcare Ltd
Key points
- Sigma's Normalised EBIT growth in line with Chemist Warehouse's 1H FY25 results
- Transaction costs of $42.4m incurred to 31 March 2025
- Sigma results for FY25 will comprise 12 months of Chemist Warehouse financial information
Full summary
Sigma Healthcare Limited (Sigma) has provided an update on the Group's trading performance following the completion of the merger with Chemist Warehouse Group (CWG) on 12 February 2025. For the nine months to 31 March 2025, Sigma's Normalised EBIT (unaudited) growth compared to the prior corresponding period (pcp) for CWG is broadly consistent with the 36% growth achieved by CWG for 1H FY25 compared to 1H FY24. Normalised EBIT is defined as Earnings Before Interest and Tax and excludes merger-related transaction costs and purchase price allocation related impacts. Transaction costs of $42.4m have been incurred to 31 March 2025, with $8.1m incurred in 1H FY25 and $34.3m incurred in Q3 FY25. The legal acquisition by Sigma of CWG will be a reverse acquisition under AASB 3 Business Combinations, with CWG treated as the accounting acquirer and Sigma treated as the accounting acquiree. Sigma's results for the 12 months ending 30 June 2025 will comprise 12 months of CWG financial information consolidating Sigma financial information from the merger completion date of 12 February 2025. As such, transaction costs incurred by Sigma prior to the merger date will not be included in the FY25 consolidated financials.